An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

Inclusion Criteria

• •Participants with a diagnosis of moderate to severe Ulcerative colitis (UC).
• •Participants initiating upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study.
• •Participants prescribed upadacitinib in accordance with the approved local label.
• •Participants able to understand and communicate with the investigator and comply with the requirements of the study.
• •Participants willing to continue with study documentation after cessation of upadacitinib.
• •Participants willing and able to participate in the collection of patient-reported data via cloud based mobile application using the provided smart device (iPhone).